Time Commitment: 4 hours and 30 minutes over 56 days
Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC Points

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login



Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology

Abigail Shockley

MD Anderson Cancer Center
Clinical Pharmacy Specialist

Dr. Abigail Shockley is a professional in the field of pharmacy, specializing in breast medical oncology. Dr. Abigail Shockley obtained a Doctor of Pharmacy (Pharm.D.) degree from Purdue University, during her time at Purdue, Dr. Shockley developed a deep understanding of the intricacies of pharmaceutical science and acquired the necessary skills to provide comprehensive patient care.

Following graduation, Dr. Shockley pursued a PGY1 General Residency at MUSC Health (Medical University of South Carolina) in order to broaden her clinical knowledge and skills. This intensive program provided exposure to various aspects of pharmaceutical care, enabling Dr. Shockley to refine her expertise in patient-centered practice.

Driven by a passion for oncology, Dr. Shockley further specialized in this field by completing a PGY2 Oncology Residency at MUSC Health Hollings Cancer Center. This rigorous training equipped her with advanced skills in managing complex oncology treatments, optimizing therapy outcomes, and providing personalized care to cancer patients.

With a solid foundation in oncology pharmacy, Dr. Abigail Shockley is currently based at MD Anderson Cancer Center, one of the world's most renowned cancer treatment centers, Dr. Shockley plays a pivotal role in the multidisciplinary care team.

As a specialist in breast medical oncology, Dr. Shockley leverages her in-depth knowledge of oncology medications, treatment guidelines, and emerging therapies to optimize treatment plans for patients with breast cancer. She collaborates closely with oncologists, nurses, and other healthcare professionals to ensure the delivery of the most effective and personalized care.

In addition to her clinical responsibilities, Dr. Shockley actively contributes to research initiatives and engages in continuing education to stay up to date with the latest advancements in the field of oncology pharmacy. She is dedicated to improving patient outcomes, exploring innovative therapies, and sharing her expertise through professional presentations and publications.

With a commitment to patient-centered care, an expertise in breast medical oncology, and a dedication to advancing the field of oncology pharmacy, Dr. Abigail Shockley continues to make significant contributions to the fight against cancer and the improvement of patient outcomes.